Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Amgen, ATM, baby, backstopped, biomarker, Bridge, chart, Chicago, closure, de, Deposit, deprioritization, deprioritize, discontinue, discontinued, diversifying, eGFR, energy, epidemic, explanatory, faster, FDIC, fifty, Filtration, float, Glomerular, guideline, heart, IgE, IgM, inclusion, inflationary, kg, Kinpeygo, Likewise, Lonza, Mexico, mimic, notwithstanding, novo, outpace, plateauing, receivership, RELYVRIO, seventeen, Silicon, Singapore, titer, unemployment, University, UPCR, Valley, xenotransplant, xenotransplantation
Removed:
accessed, accessible, accounted, aerosol, applying, ASC, ASU, attractive, awarded, Barberich, children, Codification, combining, complaint, confer, consummated, create, David, derivative, disrupted, District, exhibit, existed, FASB, Flesher, freestanding, fundamental, galeterone, granting, Gregory, Harrison, hearing, Hedging, herewith, immaterial, incorporate, IPO, Jodie, Joseph, Kalowski, Kessler, left, meaningful, misleading, Morrison, motion, moved, nasal, notify, opposing, opposition, optional, ordered, Peter, plaintiff, practical, predecessor, promissory, purported, reached, regular, reliable, reply, resulted, reverse, separation, Seth, showed, substantive, surviving, tangible, Timothy, Tokai, Topic, ultimate, unspecified, utility, Yanchik
Filing tables
Filing exhibits
Related press release
Associated ELDN transcripts
ELDN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in Registration Statement Nos. 333-200413, 333-203032, 333-210058, 333-216432, 333-232428, 333-237380 and 333-255173 on Form S-8 and Registration Statement Nos. 333-251305 and 333-254890 on Form S-3 of our report dated March 30, 2023 (which includes an explanatory paragraph regarding Eledon Pharmaceuticals, Inc.’s ability to continue as a going concern), relating to the consolidated financial statements of Eledon Pharmaceuticals, Inc., appearing in this Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc. for the year ended December 31, 2022.
/s/ KMJ Corbin & Company LLP
Irvine, California
March 30, 2023
|
|
|